ASX:SPL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

AU$690.3m

Last Updated

2021/06/19 08:06 UTC

Data Sources

Company Financials

Executive Summary

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Starpharma Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SPL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SPL's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-1.4%

SPL

-5.7%

AU Pharmaceuticals

0.2%

AU Market


1 Year Return

49.1%

SPL

-2.2%

AU Pharmaceuticals

27.7%

AU Market

Return vs Industry: SPL exceeded the Australian Pharmaceuticals industry which returned -2.2% over the past year.

Return vs Market: SPL exceeded the Australian Market which returned 27.7% over the past year.


Shareholder returns

SPLIndustryMarket
7 Day-1.4%-5.7%0.2%
30 Day1.8%0.3%5.3%
90 Day-16.3%-15.3%8.8%
1 Year49.1%49.1%-2.1%-2.2%31.8%27.7%
3 Year49.8%49.8%-44.8%-45.3%33.7%17.7%
5 Year161.5%161.5%-39.3%-42.2%75.1%42.0%

Long-Term Price Volatility Vs. Market

How volatile is Starpharma Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Starpharma Holdings undervalued compared to its fair value and its price relative to the market?

9.9x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SPL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SPL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SPL is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: SPL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SPL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SPL is overvalued based on its PB Ratio (9.9x) compared to the AU Pharmaceuticals industry average (3.1x).


Future Growth

How is Starpharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

67.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Starpharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Starpharma Holdings performed over the past 5 years?

7.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SPL is currently unprofitable.

Growing Profit Margin: SPL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SPL is unprofitable, but has reduced losses over the past 5 years at a rate of 7.5% per year.

Accelerating Growth: Unable to compare SPL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-35.1%).


Return on Equity

High ROE: SPL has a negative Return on Equity (-27.59%), as it is currently unprofitable.


Financial Health

How is Starpharma Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: SPL's short term assets (A$75.7M) exceed its short term liabilities (A$7.4M).

Long Term Liabilities: SPL's short term assets (A$75.7M) exceed its long term liabilities (A$878.0K).


Debt to Equity History and Analysis

Debt Level: SPL is debt free.

Reducing Debt: SPL has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SPL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SPL has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 8.8% each year


Dividend

What is Starpharma Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SPL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SPL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SPL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SPL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SPL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.0yrs

Average board tenure


CEO

Jackie Fairley (57 yo)

14.92yrs

Tenure

AU$1,447,571

Compensation

Dr. Jacinth K. Fairley, also known as Jackie, B.Sc., B.V.Sc.(Hons), MBA, GAICD, FTSE, has been the Chief Executive Officer of Starpharma Holdings Limited since July 1, 2006 and serves as its Managing Direc...


CEO Compensation Analysis

Compensation vs Market: Jackie's total compensation ($USD1.09M) is above average for companies of similar size in the Australian market ($USD703.92K).

Compensation vs Earnings: Jackie's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: SPL's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9%.


Top Shareholders

Company Information

Starpharma Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Starpharma Holdings Limited
  • Ticker: SPL
  • Exchange: ASX
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$690.333m
  • Shares outstanding: 406.08m
  • Website: https://starpharma.com

Location

  • Starpharma Holdings Limited
  • 4-6 Southampton Crescent
  • Abbotsford
  • Victoria
  • 3067
  • Australia

Listings


Biography

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel,...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/19 08:06
End of Day Share Price2021/06/18 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.